Novartis receives two landmark European authorisations for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis

Novartis has announced that the European Commission (EC) has granted authorisation for Cosentyx® (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic…



Source link

Would you like to get the test?